Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
12/17/2001Meridian Bioscience Reaffirms Sales and Earnings Guidance and Provides Other Information
CINCINNATI--(BW HealthWire)--Dec. 17, 2001--Meridian Bioscience, Inc., (Nasdaq:VIVO) This fiscal year earnings guidance of $0.38 to $0.43 per share, fully diluted First quarter earnings guidance of $0.07 to $0.08 per share, fully diluted Viral Antigens expansion - capital expenditure - key growth strategy Fully funded business plan - sound balance sheet - positive cash flow Cash dividend rate recently i... 
 Printer Friendly Version
11/20/2001Meridian Bioscience Expands Product Introduction to the Japanese Healthcare Market
CINCINNATI--(BW HealthWire)--Nov. 20, 2001--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that its Japanese distributor, TFB, Inc. of Tokyo, Japan, filed a request to market Meridian's ImmunoCard STAT!(R)Adenovirus test with the Japanese Ministry of Health. ImmunoCard STAT! Adenovirus is a rapid point-of-care test for direct detection of the virus that can cause conjunctivitis, pharyngitis, or gastrointestinal disease. The test is simple to perform and pr... 
 Printer Friendly Version
11/14/2001Meridian Bioscience Declares Regular Cash Dividend, Increases Regular Cash Dividend Rate and Reaffirms Sales and Earnings Guidance for Fiscal 2002
CINCINNATI, Nov 14, 2001 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today (i) declared the regular cash dividend for the fourth quarter ended September 30, 2001; (ii) increased the regular cash dividend rate for fiscal 2002; and reaffirmed sales and earnings per share guidance for fiscal 2002, as follows: Fiscal 2001 Fourth Quarter Regular Cash Dividend The Board of Directors declared the regular quarterly cash dividend of $0.065 per share for the fourth qua... 
 Printer Friendly Version
11/14/2001Meridian Reports Fiscal 2001 Year End and Profitable Fourth Quarter Operating Results
CINCINNATI, Nov 14, 2001 (BW HealthWire) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today reported operating results for the fourth quarter and for the fiscal year ended September 30, 2001. Fourth Quarter Operating Results Net earnings for the fourth fiscal quarter ended September 30, 2001, were $171,000, or $0.01 per share. Net sales for the fourth fiscal quarter were $13,501,000 compared to $13,850,000 for the same period of the prior fiscal year, a decrease of $349,000 or... 
 Printer Friendly Version
11/8/2001Meridian Announces Agreements With Thermo Electron Corporation for the Immediate Distribution of Infectious Disease Tests for Influenza, C. difficile, E. coli and Rotavirus
CINCINNATI, Nov 8, 2001 (BW HealthWire) -- Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has signed two agreements for the distribution of important infectious disease tests with Thermo Electron Corporation (NYSE:TMO) Under the terms of the agreements, Meridian will immediately begin marketing Thermo Electron's new point-of-care tests for influenza and C. difficile in the U.S. These test kits utilize Thermo Electron's Thermo Biostar proprietary Optic... 
 Printer Friendly Version
10/22/2001Meridian Announces Distribution Agreement With ScheBo Biotech AG for the Distribution in Italy of a Novel Test for Pancreatic Dysfunction
CINCINNATI, Oct 22, 2001 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it's subsidiary Meridian Bioscience Europe Srl., has signed a Distribution Agreement with ScheBo(R)Biotech AG, a fast growing German biotechnology company, to market ScheBo Pancreatic Elastase-1 Stool Test, a non-invasive, novel test for the detection and quantification of human pancreatic elastase-1. Pancreatic Elastase-1 is an indicator of pancreatic exocrine insufficiency, which... 
 Printer Friendly Version
10/9/2001Meridian Bioscience Provides Guidance for Fiscal 2002 and Reports On Capital Adequacy and Other Matters
CINCINNATI--(BW HealthWire)--Oct. 9, 2001--Meridian Bioscience, Inc. (Nasdaq:VIVO) today provided guidance to the financial community with respect to its operating projections for the current fiscal year ending September 30, 2002. Based on Meridian's recently completed business planning and budgeting activities, management expects net sales to be in the range of $62 -- $65 million and fully diluted earnings per share of between $0.38 and $0.43 for fiscal 2002. ... 
 Printer Friendly Version
8/16/2001Broadlane Awards Contract to Meridian Bioscience
CINCINNATI, Aug 16, 2001 (BW HealthWire) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced it has been awarded a three-year contract from Broadlane Inc., a leader in delivering supply chain services to the healthcare industry. The contract includes Meridian's full line of parasitological transport devices and several of its microbiological diagnostic products used in the detection of gastrointestinal, bacterial, and parasitic infections. Meridian's newest product for the detec... 
 Printer Friendly Version
7/24/2001Meridian Reports Profitable Third Quarter Operating Results and Declares Regular Cash Dividend
CINCINNATI--(BW HealthWire)--July 24, 2001--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today reported operating results for the third quarter and for the nine months ended June 30, 2001 and declared the regular cash dividend, as follows: Third Quarter Operating Results Net sales for the third fiscal quarter ended June 30, 2001, were $13,906,000 as compared to $14,340,000 for the same period of the prior fiscal year, a decrease of $434,000 or 3%. Ex... 
 Printer Friendly Version
6/7/2001Meridian Announces First Preview of UPlink Technology At 2001 American Society of Microbiology Meeting
CINCINNATI, Jun 7, 2001 (BW HealthWire) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that its highly sensitive, novel UPlink(TM) technology was previewed in a poster session at the 2001 American Society for Microbiology Conference, held in Orlando, FL. Meridian and its partner, OraSure Technologies, Inc., demonstrated, for the first time, the unique abilities of the phosphor-based UPlink technology in the detection of infectious disease. Meridian and OraSure have an exclu... 
 Printer Friendly Version
5/29/2001Meridian Bioscience Hires Vice President of Regulatory Affairs and Quality Systems
CINCINNATI--(BW HealthWire)--May 29, 2001--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced it has hired Susan Rolih as its Vice President of Regulatory Affairs and Quality Systems. Most recently, Ms. Rolih was Corporate Vice President - Regulatory Affairs and Quality Assurance at Immucor, Inc., Norcross, GA. She previously held titles of Vice President-Regulatory Affairs and Quality Assurance and Vice President-Technical Services. Ms. Rolih has extensive experience in manag... 
 Printer Friendly Version
5/22/2001Meridian Bioscience Reports On Profitable Operations, Increased Production and Plans to Expand Credit Facility
CINCINNATI--(BW HealthWire)--May 22, 2001--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced operating results for the month of April were profitable, consistent with the Company's earlier public statements that it expected operating results would become profitable during the current quarter. Quoting from the April 24, 2001, press release, "Notwithstanding the operating losses reported for the second quarter and first half of fiscal 2001, meaningful progress has been made in i... 
 Printer Friendly Version
5/14/2001Meridian Announces Patent Filing Describing the Correlation of Colic and H. pylori Infection in Infants
CINCINNATI--(BW HealthWire)--May 14, 2001--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has filed both a U.S. Patent Application and an International Application under the Patent Cooperation Treaty directed to the diagnosis of Helicobacter pylori (H. pylori) associated colic in infants and its treatment with antibiotic and other therapies. H. pylori infection has also been implicated in gastroduodenal diseases such as peptic ulcers, gastritis, and stomach cancer.... 
 Printer Friendly Version
4/24/2001Meridian Reports Second Quarter Results, Declares Regular Cash Dividend and Announces Stock Buyback Program
CINCINNATI, Ohio--(BW HealthWire)--April 24, 2001--Meridian Bioscience, Inc. (Nasdaq:VIVO), today reported operating results for the second quarter and six months ended March 31, 2001, declared the regular cash dividend and announced a stock buyback plan, as follows: Second Quarter Operating Results Net sales for the second fiscal quarter ended March 31, 2001, were $13,866,000 as compared to $14,577,000 for the same period of the prior fiscal year, a decrease of ... 
 Printer Friendly Version
4/12/2001Meridian Bioscience Launches Rapid One-Step Test for Direct Detection of Cryptosporidium and Giardia
CINCINNATI--(BW HealthWire)--April 12, 2001--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has launched a new rapid, one-step device for the simultaneous detection of two waterborne parasites, Giardia and Cryptosporidium. ImmunoCard STAT!(R) Cryptosporidium/Giardia, gives accurate, easy-to-read results in just minutes. Giardia lamblia and Cryptosporidium are waterborne parasites causing acute diarrhea and gastrointestinal dist... 
 Printer Friendly Version
4/2/2001Meridian Bioscience Hires Vice President of Operations
CINCINNATI--(BUSINESS WIRE)--April 2, 2001--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced it has hired Larry Baldini as its Vice President of Operations. Most recently, Mr. Baldini was Director of Operations (Sensory Systems) at Instrumentation Laboratories, Ann Arbor, MI; he previously held the titles of Operations Manager and Facilities Manager. Mr. Baldini has extensive experience in managing a wide variety of operations, including implementing quality systems (QSRs an... 
 Printer Friendly Version
3/28/2001Meridian Bioscience Announces Important Supply Contract and Comments on Return to Profitable Operations and Capital Adequacy
CINCINNATI--(BW HealthWire)--March 28, 2001--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced it has entered into a long-term supply agreement with Zeus Scientific, Inc. for 27 products to be marketed under the Meridian Bioscience brand name. Zeus Scientific, headquartered in Raritan, New Jersey, is a well-established and highly regarded developer and producer of infectious disease serology products. The launch date for the Zeus-manufactured, Meri... 
 Printer Friendly Version
2/9/2001Meridian Announces Fiscal Year 2001 First Quarter Results
CINCINNATI--(BW HealthWire)--Feb. 9, 2001--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced net sales for the first fiscal quarter that ended December 31, 2000, of $15,254,000 compared to $14,329,000 for the corresponding period of the prior fiscal year. Meridian reported a net loss of ($8,192,000) or ($0.56) per share for the first quarter of fiscal 2001, reflecting charges for its European restructuring plan ($657,000, after tax) and other charges of ($8,500,000, ... 
 Printer Friendly Version
1/24/2001Meridian Announces Name Change and Declares Dividend for First Quarter
CINCINNATI--(BW HealthWire)--Jan. 24, 2001--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that yesterday shareholders formally approved Meridian's name change. Henceforth, the Company will be Meridian Bioscience, Inc. and trade under the symbol VIVO. Meridian's Board of Directors declared a dividend of $0.065 per share to be paid February 8, 2001 to shareholders of record as of February 1, 2001. The regular quarterly cash dividend is at an indicated annual rate o... 
 Printer Friendly Version
1/8/2001Meridian Diagnostics, Inc., dba Meridian Bioscience, Inc. Announces Ticker Symbol Change
CINCINNATI--(BW HealthWire)--Jan. 8, 2001--Meridian Bioscience, Inc. today announced that effective with commencement of trading tomorrow morning, the Nasdaq ticker symbol for its common stock will be VIVO. As mentioned in the Company's annual report to shareholders, Meridian has moved rapidly beyond its original mission as a manufacturer and distributor of high-quality diagnostic test kits. Our strategies have been broadened to encompass participation in the rapidly evol... 
 Printer Friendly Version